La-Iii
Brand names,
La-Iii
Analogs
La-Iii
Brand Names Mixture
La-Iii
Chemical_Formula
C16H13ClN2O
La-Iii
RX_link
http://www.rxlist.com/cgi/generic/diazepam.htm
La-Iii
fda sheet
La-Iii
msds (material safety sheet)
La-Iii
Synthesis Reference
Reeder, Sternbach; U.S. Pat. 3,371,085 (1968)
La-Iii
Molecular Weight
284.74 g/mol
La-Iii
Melting Point
125-126oC
La-Iii
H2O Solubility
Slightly soluble (50 mg/L)
La-Iii
State
solid
La-Iii
LogP
2.988
La-Iii
Dosage Forms
Tablets; Injectable solution
La-Iii
Indication
Used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome.
La-Iii
Pharmacology
Diazepam, a benzodiazepine, generates the same active metabolite as chlordiazepoxide and clorazepate. In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.
La-Iii
Absorption
Essentially complete, with a bioavailability of 93%.
La-Iii
side effects and Toxicity
Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
La-Iii
Patient Information
La-Iii
Organisms Affected
Humans and other mammals